evorpacept, KEYTRUDA 25 mg/mL concentrate for solution for infusion clinical trials

A PHASE 2 STUDY OF ALX148 IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA (ASPEN-03)

This study looks at a new treatment called ALX148 combined with an existing cancer drug, pembrolizumab (Keytruda), for advanced head and neck cancer. Researchers want to see if this combination helps shrink tumours or stop them from growing.